Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD)
- PMID: 22934689
- PMCID: PMC3535176
- DOI: 10.1111/j.1468-1293.2012.01038.x
Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD)
Abstract
Objectives: The objective of the study was to conduct a within-cohort assessment of risk factors for incident AIDS-defining cancers (ADCs) and non-ADCs (NADCs) within the Australian HIV Observational Database (AHOD).
Methods: A total of 2181 AHOD registrants were linked to the National AIDS Registry/National HIV Database (NAR/NHD) and the Australian Cancer Registry to identify those with a notified cancer diagnosis. Included in the current analyses were cancers diagnosed after HIV infection. Risk factors for cancers were also assessed using logistic regression methods.
Results: One hundred and thirty-nine cancer cases were diagnosed after HIV infection among 129 patients. More than half the diagnoses (n = 68; 60%) were ADCs, of which 69% were Kaposi's sarcoma and 31% non-Hodgkin's lymphoma. Among the NADCs, the most common cancers were melanoma (n = 10), lung cancer (n = 6), Hodgkin's lymphoma (n = 5) and anal cancer (n = 5). Over a total of 21021 person-years (PY) of follow-up since HIV diagnosis, the overall crude cancer incidence rate for any cancer was 5.09/1000 PY. The overall rate of cancers decreased from 15.9/1000 PY [95% confidence interval (CI) 9.25-25.40/1000 PY] for CD4 counts < 100 cells/μL to 2.4/1000 PY (95% CI 1.62-3.39/1000 PY) for CD4 counts > 350 cells/μL. Lower CD4 cell count and prior AIDS diagnoses were significant predictors for both ADCs and NADCs.
Conclusions: ADCs remain the predominant cancers in this population, although NADC rates have increased in the more recent time period. Immune deficiency is a risk factor for both ADCs and NADCs.
© 2012 British HIV Association.
Similar articles
-
Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009.HIV Med. 2013 Sep;14(8):481-90. doi: 10.1111/hiv.12034. Epub 2013 Apr 7. HIV Med. 2013. PMID: 23560682
-
Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.AIDS. 2014 Sep 10;28(14):2109-18. doi: 10.1097/QAD.0000000000000382. AIDS. 2014. PMID: 25265077
-
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30. doi: 10.1093/jnci/92.22.1823. J Natl Cancer Inst. 2000. PMID: 11078759
-
AIDS malignancies in the era of highly active antiretroviral therapy.Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70. Oncology (Williston Park). 2002. PMID: 12108891 Review.
-
The epidemiology of acquired immunodeficiency syndrome malignancies.Semin Oncol. 2000 Aug;27(4):390-401. Semin Oncol. 2000. PMID: 10950365 Review.
Cited by
-
Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection.Front Microbiol. 2013 Oct 18;4:311. doi: 10.3389/fmicb.2013.00311. eCollection 2013. Front Microbiol. 2013. PMID: 24151490 Free PMC article. Review.
-
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.HIV Med. 2018 Feb;19(2):102-117. doi: 10.1111/hiv.12557. Epub 2017 Oct 6. HIV Med. 2018. PMID: 28984429 Free PMC article.
-
Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients.Sci Rep. 2022 Aug 1;12(1):13196. doi: 10.1038/s41598-022-17237-5. Sci Rep. 2022. PMID: 35915124 Free PMC article.
-
Non-Hodgkin lymphoma risk in adults living with HIV across five continents.AIDS. 2018 Nov 28;32(18):2777-2786. doi: 10.1097/QAD.0000000000002003. AIDS. 2018. PMID: 30234606 Free PMC article.
-
Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy.Clin Infect Dis. 2013 Sep;57(5):756-64. doi: 10.1093/cid/cit369. Epub 2013 Jun 4. Clin Infect Dis. 2013. PMID: 23735330 Free PMC article.
References
-
- Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIVx/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 Jul 7;370(9581):59–67. - PubMed
-
- Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008 May 20;148(10):728–36. - PubMed
-
- Grulich AE. Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS. 2009 May;4(3):183–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials